Bristol Myers Squibb Return on Tangible Equity 2010-2022 | BMY

Current and historical return on tangible equity values for Bristol Myers Squibb (BMY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Bristol Myers Squibb Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $6.25B $-28.96B -21.58%
2021-12-31 $6.99B $-27.02B -23.20%
2021-09-30 $-5.41B $-28.17B 16.70%
2021-06-30 $-5.08B $-31.72B 15.84%
2021-03-31 $-6.22B $-33.67B 19.56%
2020-12-31 $-9.02B $-35.91B 28.26%
2020-09-30 $-0.04B $-26.99B 0.14%
2020-06-30 $-0.56B $-30.59B 2.52%
2020-03-31 $0.95B $-34.14B -7.63%
2019-12-31 $3.44B $-34.76B -168.95%
2019-09-30 $5.66B $10.24B 68.31%
2019-06-30 $6.20B $8.62B 86.05%
2019-03-31 $5.14B $7.76B 82.78%
2018-12-31 $4.92B $6.50B 89.34%
2018-09-30 $1.43B $5.96B 29.67%
2018-06-30 $0.38B $4.65B 7.45%
2018-03-31 $0.92B $4.93B 16.52%
2017-12-31 $1.01B $3.77B 16.99%
2017-09-30 $4.23B $6.84B 60.37%
2017-06-30 $4.59B $6.72B 63.88%
2017-03-31 $4.84B $6.38B 67.11%
2016-12-31 $4.46B $8.09B 62.04%
2016-09-30 $3.37B $7.53B 50.29%
2016-06-30 $2.87B $6.82B 44.12%
2016-03-31 $1.57B $6.30B 24.26%
2015-12-31 $1.57B $6.12B 23.53%
2015-09-30 $1.78B $6.78B 26.60%
2015-06-30 $1.79B $6.75B 27.17%
2015-03-31 $2.25B $6.96B 34.55%
2014-12-31 $2.00B $6.20B 31.55%
2014-09-30 $2.72B $6.44B 43.43%
2014-06-30 $2.69B $6.49B 61.51%
2014-03-31 $2.89B $6.28B 123.71%
2013-12-31 $2.56B $5.82B 1850.54%
2013-09-30 $2.76B $-1.11B -137.31%
2013-06-30 $1.36B $-1.64B -55.71%
2013-03-31 $1.47B $-2.52B -160.20%
2012-12-31 $1.96B $-2.78B 224.85%
2012-09-30 $1.89B $-2.82B 56.20%
2012-06-30 $3.56B $4.44B 59.61%
2012-03-31 $3.82B $4.63B 56.24%
2011-12-31 $3.70B $7.16B 49.52%
2011-09-30 $3.32B $7.68B 44.64%
2011-06-30 $3.30B $7.69B 44.03%
2011-03-31 $3.33B $7.37B 44.54%
2010-12-31 $3.09B $7.04B 41.55%
2010-09-30 $10.63B $7.92B 144.49%
2010-06-30 $10.64B $7.59B 153.87%
2010-03-31 $10.70B $7.20B 152.23%
2009-12-31 $10.59B $6.70B 150.77%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.597B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00